Standard Podcast [34:01m]: Play Now | Play in Popup | Download

Heart of Health - do you have one?

Part I of Effective Alternatives for Treating Cardiovascular Disease – EDTA Chelation as Front-Runner

Dr. Douglass Interview with Dr. Ronald Hoffman on Health Talk, WOR Radio 710, New York City, N.Y., discussing the relative worthlessness of bypass surgery and angioplasty for stable heart disease. Click here to listen.

EDTA chelation therapy could result in profound health care cost savings, which are sorely needed with the current financial crisis the world is in. And with the prospects of massive tax increases and socialized medicine under an Obama administration probably doesn’t make the outlook much better. An example of research showing the potential cost savings from EDTA chelation comes from a study done by Danish physician Dr. Clause Hancke: 90% of his patients who were on the waiting list for getting coronary artery bypass surgery or leg amputation due to poor circulation to their legs, were able to cancel their surgeries after a course of intravenous EDTA chelation treatments. Imagine the potential for financial savings and real health improvements.

Basics of EDTA Chelation: EDTA – Ethylene-diamine-tetra-acetate - is one of many ‘chelating agents’. The ‘chel’ (pronounced keel) in chelation (”kee-LAY-shun”) comes from the Greek for ‘claw.’ Chelating agents, chelation drugs ‘claw’ strongly onto metals and minerals in our blood, cells, tissues and organs and are then ‘flushed’ out of the body, primarily through the kidneys. The attraction between EDTA, and say lead (or other positively charged atoms) is through electromagnetic forces, not ‘covalent’ chemical bonding. EDTA’s has varying attractions for different metals. For example, if an EDTA-calcium complex comes into the presence of lead, the EDTA will have a higher electromagnetic attraction for lead and thereby preferentially bind to the lead, and release the calcium in to the body, allowing for the efficient removal of lead through the kidneys (and a small amount of elimination through the bowels). It is a true ‘detoxification’ therapy.

EDTA chelation therapy is not ‘natural.’ It is a synthetic amino acid approved by the FDA for treating lead toxicity, not cardiovascular disease. Use of EDTA for treating cardiovascular disease is considered ‘off-label’ use of the drug. The controversy of EDTA chelation is primarily around the financial implications it has, as a replacement for bypass surgery and angioplasty. Listeners will recall from last week that entire ‘industries’ have been built around bypass surgery and angioplasty, and that these two procedures do not extend life or even decrease the rate of subsequent heart attacks in people with stable heart disease.

History of EDTA Chelation for Treating Cardiovascular Disease: The benefits were discovered serendipitously in the 1950s. Cardiologist Dr. Norman C. Clarke reported that while treating a patient for lead toxicity who happened to have angina symptoms at the time, that the patient told Dr. Clarke that his chest pains lessened. Dr. Clarke reported his earliest findings – his empirical, experience-based discoveries – in the American Journal of Medical Sciences and the American Journal of Cardiology. Since then, numerous studies and clinical reports have been published supporting EDTA’s efficacy for the treatment of cardiovascular disease. An excellent resource for finding published studies on EDTA chelation for cardiovascular disease: Saunder’s textbook, Cardiovascular Drug Therapy chapter titled “Magnesium EDTA Chelation.” Other resources: www.drcranton.com/chelation.htm and www.acam.org.

Scientific studies on EDTA Chelation for Cardiovascular Disease. We discuss a few of the published studies. It appears, in general, from the research and from clinical experience (when treating patients who are not diabetic and who do not smoke cigarettes), that 75%-90% of patients experience significant improvement in their symptoms, such as chest pain and exercise-induced leg pain, after a course of intravenous EDTA chelation treatments. Some research supports EDTA chelation as being of benefit to cerebrovascular disease too (improving arterial circulation to the brain). The ultimate question becomes, when is the evidence enough?

Good medicine word of the week: EDTA chelation - the intravenous administration of an FDA-approved drug, used ‘off-label,’ for the treatment of cardiovascular diseases, including poor circulation to the heart, legs and brain; to the entire body, in fact.

Next Week: Part II Effective Alternatives for Treating Cardiovascular Disease – EDTA chelation as Front-Runner! Maverick doctors challenged legally by state and federal governments win their cases thereby foiling attempts to take away our freedoms to use EDTA chelation for treating cardiovascular disease.